USPTO Examiner DABKOWSKI ERINNE R - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19197254Vaccines against Chlamydia sp.May 2025March 2026Allow1021YesNo
18654900PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTINMay 2024December 2025Allow1911YesNo
18603127METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINSMarch 2024January 2026Abandon2211NoNo
18436355SCAFFOLD PROTEINSFebruary 2024December 2024Allow1001NoNo
18420397TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2AJanuary 2024May 2025Abandon1611NoNo
18412585NOVEL PTH MIMETIC PEPTIDE BASED ON PROTEIN DOMAIN RECONSTRUCTION AND APPLICATION THEREOFJanuary 2024May 2025Allow1610YesNo
18393925METHODS OF SCAR PREVENTION AND/OR TREATMENTDecember 2023October 2025Abandon2221NoNo
18513575Method for Side Effect Reduction in the Use of Statins Via Physiologically Synthesized GlutathioneNovember 2023April 2025Abandon1621NoNo
18505472WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAMENovember 2023December 2024Abandon1321YesNo
18497741CYSTINE KNOT SCAFFOLD PLATFORMOctober 2023January 2025Abandon1510NoNo
18497081APELIN POLYPEPTIDESOctober 2023February 2026Allow2711YesNo
18497900PEPTIDE COMPOSITION AND RESPECTIVE USESOctober 2023April 2025Allow1821NoNo
18491530METHODS AND COMPOSITIONS FOR TREATING CD44+ CANCERSOctober 2023July 2024Abandon901NoNo
18480170SYNTHETIC PEPTIDE COMPOUNDS AND METHODS OF USEOctober 2023January 2025Allow1511YesNo
18449039DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONSAugust 2023October 2025Abandon2611NoNo
18366653LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USEAugust 2023March 2025Allow1911YesNo
18228879METHODS OF TREATING METASTATIC CANCERS USING AXL DECOY RECEPTORSAugust 2023December 2025Abandon2921NoNo
18228099PHOSPHORYLCHOLINE-TUFTSIN CONJUGATE FOR TREATING OCULAR INFLAMMATIONJuly 2023September 2025Abandon2521NoNo
18356944Alkali-Tolerant Affinity Chromatography LigandsJuly 2023January 2026Allow3031YesNo
18352800IN VIVO SYNTHESIS OF ELASTIC FIBERJuly 2023March 2025Abandon2011NoNo
18217834ELEVATED INTRACRANIAL PRESSURE TREATMENTJuly 2023September 2024Abandon1510NoNo
18210179PEPTIDE DERIVED FROM PEP27 PEPTIDE AND USES THEREOFJune 2023August 2024Allow1411YesNo
18334287PEPTIDE COMPOSITION AND RESPECTIVE USESJune 2023July 2024Allow1421NoNo
18310188PEPTIDE MODULATORS OF THE INTERACTION BETWEEN HUMAN C-PEPTIDE AND HUMAN ELASTIN RECEPTOR FOR THERAPEUTIC USEMay 2023May 2025Abandon2521NoNo
18194372PEPTIDE COMPOSITION AND RESPECTIVE USESMarch 2023June 2024Allow1511YesNo
18015975POLYPEPTIDE FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAMEJanuary 2023December 2025Allow3510YesNo
18151910ANTIVIRAL COMPOSITIONS AND METHODSJanuary 2023February 2024Abandon1310NoNo
18079604METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILUREDecember 2022June 2024Allow1821NoNo
18057065METHOD OF TREATING PRADER-WILLI SYNDROMENovember 2022February 2026Abandon3931NoNo
17926095METHODS AND COMPOSITIONS FOR TREATING SARS-COV-2 INFECTION USING PEPTIDE NUCLEIC ACID-BASED AGENTSNovember 2022March 2026Abandon4001NoNo
17998862STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTIONNovember 2022March 2026Abandon4001NoNo
17924905TREATMENT OF RESPIRATORY VIRAL INFECTIONSNovember 2022February 2026Abandon3901NoNo
18048655NOVEL PROTEIN VARIANT AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASE USING THE SAMEOctober 2022May 2024Allow1811YesNo
17917618ANTI-OBESITY PEPTIDES AND USES THEREOFOctober 2022January 2026Abandon4001NoNo
17933502POLYPEPTIDE EXPRESSED IN THE STRATUM CORNEUM AND USE THEREOFSeptember 2022September 2024Abandon2330NoNo
17819280PDL2 COMPOUNDSAugust 2022September 2024Allow2521YesNo
17875872WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAMEJuly 2022November 2023Abandon1611YesNo
17858877IN VIVO SYNTHESIS OF ELASTIC FIBERJuly 2022July 2023Abandon1301NoNo
17810776COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIERJuly 2022August 2024Allow2521YesNo
17786669ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBESJune 2022December 2025Allow4211YesNo
17843595CYSTINE KNOT SCAFFOLD PLATFORMJune 2022November 2023Abandon1710NoNo
17839264LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USESJune 2022April 2024Abandon2221NoNo
17782869PEPTIDES FOR REGULATING GLUCOSEJune 2022January 2026Abandon4311NoNo
17782376COMPOSITIONS AND METHODS EXCLUDING OR WITH REDUCED GLUTAMINE FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASSEMIASJune 2022November 2025Abandon4201NoNo
17781185PARATHYROID HORMONE ATTENUATES LOW BACK PAIN AND OSTEOARTHRITIC PAINMay 2022December 2025Abandon4301NoNo
17824641TGF-B AS A THERAPEUTIC TARGET FOR INTRACRANIAL ANEURYSMMay 2022May 2025Abandon3511NoNo
17748212TREATING ALZHEIMER'S DISEASEMay 2022December 2025Allow4311YesNo
17748163METHODS AND COMPOSITIONS FOR INHIBITING ADAM10 BIOLOGICAL ACTIVITIESMay 2022November 2024Allow3011YesNo
17737789POLYPEPTIDE AND USE THEREOFMay 2022September 2023Allow1611YesNo
17734828PEPTIDE LIBRARY AND USE THEREOFMay 2022February 2025Abandon3421NoNo
17660209METASTASIS INHIBITING PROTEINApril 2022December 2024Allow3211YesNo
17769709METHODS FOR TREATING CANCERApril 2022March 2026Abandon4711NoNo
17720422CD71 BINDING FIBRONECTIN TYPE III DOMAINSApril 2022March 2024Allow2311YesNo
17713233Method for Producing Peptide Ace InhibitorsApril 2022January 2025Abandon3311NoNo
17713140PROTOCOL FOR TREATMENT OF LUPUS NEPHRITISApril 2022January 2023Allow1011YesNo
17693978COMPOSITIONS AND METHODS FOR TREATING MYOCARDIAL INFARCTION AND ISCHEMIAMarch 2022April 2024Abandon2511NoNo
17640817ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOFMarch 2022December 2025Abandon4511NoNo
17640322ANTIVIRAL PEPTOID COMPOSITIONSMarch 2022February 2026Allow4821NoNo
17684616Composition for Collagen-Based Drink MixMarch 2022June 2024Abandon2701NoNo
17678565DAP12 CONSTRUCTS AND THEIR USE TO ENHANCE DC VACCINES AND IMMUNOTHERAPIESFebruary 2022January 2025Allow3521YesNo
17675837Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic HormoneFebruary 2022May 2024Abandon2611NoNo
17636715APTAMER ASSEMBLIES FOR PROTEIN CROSSLINKINGFebruary 2022August 2025Allow4221YesNo
17673361LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USESFebruary 2022August 2023Allow1811YesNo
17635039EXENATIDE ANALOG AND USE THEREOFFebruary 2022July 2025Allow4111YesNo
17668744METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITIONFebruary 2022August 2024Abandon3020YesNo
17634433THERAPEUTIC PEPTIDESFebruary 2022May 2025Abandon3901NoNo
17665524Method of treatment of degenerative diseases caused by membrane channel-forming peptides fragmentsFebruary 2022August 2023Abandon1901NoNo
17632512APPLICATION OF POLYPEPTIDE OR DERIVATIVE THEREOFFebruary 2022April 2025Abandon3801NoNo
17591151ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERSFebruary 2022March 2024Allow2621YesNo
17632193Premixed Ultra-Stable Single-Chain Insulin Analogue FormulationsFebruary 2022August 2025Abandon4201NoNo
17631807METHOD FOR TREATING ALZHEIMER'S DISEASE BY REGULATING AMINO ACID LEVELJanuary 2022July 2024Abandon3021NoNo
17588736NOVEL PEPTIDE DERIVED FROM PEP27 PEPTIDE AND USES THEREOFJanuary 2022September 2023Abandon2021NoNo
17597940NOVEL THERAPEUTIC USEJanuary 2022July 2025Abandon4101NoNo
17587427BIFUNCTIONAL BLOOD BRAIN THERAPIES FOR INTERLEUKIN-1 RELATED DISEASESJanuary 2022March 2024Abandon2620NoNo
17627373COMPOSITIONS AND METHODS OF TREATMENT FOR BREAST CANCER INVOLVING A NOVEL CAPER?-MLL1 COMPLEXJanuary 2022April 2025Abandon3901NoNo
17557874USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONINDecember 2021July 2024Abandon3112YesNo
17556730NEUROPROTECTIVE PEPTIDESDecember 2021February 2025Allow3831YesNo
17621178CELL-PERMEABLE PEPTIDEDecember 2021May 2025Allow4011YesNo
17554486USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONINDecember 2021December 2022Abandon1220YesNo
17551904PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST AN AGENT SELECTED FROM MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYCLIC ACID AND PARACETAMOLDecember 2021November 2025Allow4720YesNo
17618951PHARMACEUTICAL COMPOSITIONS FOR GLUCAGON AND GLP-1 CO-AGONIST PEPTIDESDecember 2021January 2025Abandon3701NoNo
17616918PLANT TREATMENTDecember 2021February 2025Abandon3801NoNo
17615201BIOACTIVE PEPTIDES AND COMPOSITIONS COMPRISING THEMNovember 2021June 2025Allow4220YesNo
17613974COLLAGEN COMPOSITIONS AND USES THEREOFNovember 2021March 2025Abandon3901NoNo
17612020CYCLODEXTRIN BASED INJECTABLE COFORMULATIONS OF SGLT2 INHIBITORS AND INCRETIN PEPTIDESNovember 2021March 2025Abandon4001NoNo
17526776METHODS FOR TREATING ARTHRITIS USING SPL-108 PEPTIDENovember 2021January 2025Abandon3801NoNo
17522115ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENTNovember 2021June 2024Abandon3121NoNo
17521425METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLSNovember 2021July 2023Allow2110YesNo
17608216STABLE ALBUVIRTIDE COMPOSITIONSNovember 2021February 2025Abandon4001NoNo
17517063ANTI-INFLAMMATORY NANOFIBERSNovember 2021August 2024Allow3431YesNo
17607765COMPOSITION FOR PREVENTION OR TREATMENT OF HAIR LOSS INCLUDING HAPLN1October 2021May 2024Allow3021NoNo
17594259MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOFOctober 2021October 2025Allow4821YesNo
17491219NOVEL TUMOR-SPECIFIC POLYPEPTIDE AND USE THEREOFSeptember 2021September 2023Allow2421YesNo
17440461PHOTOIMMUNOTHERAPY AND PHARMACEUTICAL AGENT USED THEREFORSeptember 2021March 2025Abandon4201NoNo
17477458Leucine/Peptide Composition and Method of FormulationSeptember 2021April 2023Abandon1901NoNo
17438839NOVEL ANTIMICROBIAL PEPTIDE DERIVED FROM PSEUDIN-2 PEPTIDE AND USES THEREOFSeptember 2021April 2025Allow4321NoNo
17396577Treating Inflammatory Lung DiseaseAugust 2021January 2024Allow3011YesNo
17428574METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINSAugust 2021March 2024Abandon3211NoNo
17393495ANTIMICROBIAL PEPTIDES AND COMPOSITIONS, METHODS, ARTICLES & KITS RELATING THERETOAugust 2021March 2025Allow4421YesNo
17428615AMYLOID PEPTIDE VARIANTSAugust 2021September 2025Allow5051YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DABKOWSKI, ERINNE R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
5
(55.6%)
Examiner Reversed
4
(44.4%)
Reversal Percentile
66.9%
Higher than average

What This Means

With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
29
Allowed After Appeal Filing
6
(20.7%)
Not Allowed After Appeal Filing
23
(79.3%)
Filing Benefit Percentile
27.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DABKOWSKI, ERINNE R - Prosecution Strategy Guide

Executive Summary

Examiner DABKOWSKI, ERINNE R works in Art Unit 1654 and has examined 409 patent applications in our dataset. With an allowance rate of 55.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner DABKOWSKI, ERINNE R's allowance rate of 55.3% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DABKOWSKI, ERINNE R receive 2.36 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DABKOWSKI, ERINNE R is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +66.6% benefit to allowance rate for applications examined by DABKOWSKI, ERINNE R. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 43.8% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 28.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 97.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 54% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.